Imerys (NK) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
1 Nov, 2025Executive summary
Revenue for the first nine months of 2025 was €2,583 million, down 0.7% like-for-like year-over-year, reflecting weak industrial activity in Europe and subdued demand in North America.
Adjusted EBITDA for the nine months was €421 million (16.3% margin), nearly flat year-over-year like-for-like, supported by disciplined pricing and cost management.
Net income, Group share, for the nine months reached €110 million, a significant improvement from a €143 million loss last year, mainly due to the absence of non-recurring charges.
A comprehensive cost reduction and performance improvement program has been launched to restore profitability and simplify the organization.
Strategic initiatives include the agreement to acquire SB Mineração in Brazil, advanced discussions for a minority investment in the EMILI Lithium Project, and partnerships to expand the battery materials portfolio and decarbonize operations.
Financial highlights
Q3 2025 revenue was €827 million, down 1.3% year-over-year at constant scope and exchange rates; nine-month revenue was €2,583 million, down 0.7%.
Adjusted EBITDA for Q3 2025 was €140 million (16.9% margin); nine-month adjusted EBITDA was €421 million, down 20.9% year-over-year, mainly due to lower JV contributions and FX effects.
Net income, Group share, for Q3 was €39 million, compared to a €285 million loss last year due to non-cash expenses from asset disposals.
Current net income, Group share, for nine months was €126 million, down 41.2% year-over-year.
FX impact was -€47 million, mainly from USD devaluation.
Outlook and guidance
Full-year 2025 adjusted EBITDA guidance is confirmed at €540–580 million, assuming stable macroeconomic conditions and exchange rates.
No significant market recovery is expected in the near term; cost actions are being accelerated to restore profitability.
European volumes are expected to improve in Q4, aided by anti-dumping measures on Chinese mineral imports.
U.S. recovery is anticipated in the second half of 2026; Europe is expected to rebound next year, though the magnitude is uncertain.
Latest events from Imerys
- Stable 2025 results, major goodwill impairment, and cost savings plus lithium investment ahead.NK
Q4 202520 Feb 2026 - Strong 2024 results, higher dividend, strategic progress, and all resolutions approved.NK
AGM 20253 Feb 2026 - H1 2024 adjusted EBITDA rose 11% to €384m, margin 20%, with strong cash flow and guidance.NK
H1 20242 Feb 2026 - Nine-month EBITDA margin rose to 19.2% as full-year guidance is confirmed.NK
Q3 202417 Jan 2026 - Organic growth and sustainability progress offset margin pressure from joint venture declines.NK
Q1 202524 Dec 2025 - Organic growth, margin expansion, and strong ESG progress with robust 2025 outlook.NK
H2 202415 Dec 2025 - Stable H1 2025 sales and EBITDA, but net income fell; full-year EBITDA guidance reaffirmed.NK
Q2 202516 Nov 2025